[144] Teladoc Health, Inc. SEC Filing

Rhea-AI Filing Summary

Teladoc Health, Inc. (TDOC) Form 144 summary: This notice reports a proposed sale of 4,700 common shares through Fidelity Brokerage Services with an aggregate market value of $35,650.91, to be executed approximately on 09/02/2025 on the NYSE. The shares were acquired on 08/29/2025 as restricted stock vesting and were paid as compensation. The filing also discloses a prior sale by the same account: 4,653 shares sold on 06/02/2025 for $31,919.58. The filing includes the total number of shares outstanding reported as 176,690,662 and contains the required certification that the seller is not aware of undisclosed material adverse information.

Positive

• Complete disclosure of proposed sale details including broker, share count, aggregate market value, and exchange
• Acquisition method stated as restricted stock vesting and payment classified as compensation, improving transparency
• Prior sale disclosed (4,653 shares for $31,919.58), showing historical continuity in filings

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine insider disposition filing; small number of shares relative to outstanding common stock suggests limited market impact.

The Form 144 documents a proposed sale of 4,700 shares acquired via restricted stock vesting and marked as compensation, with an approximate market value of $35,650.91. The filing follows a prior sale of 4,653 shares that yielded $31,919.58. For investors, this type of disclosure signals an insider selling vested compensation rather than an operational development. The magnitude disclosed is small in absolute dollar terms and compared to the stated 176,690,662 shares outstanding, indicating low direct impact on float or liquidity.

Corporate Governance Expert

TL;DR: Filing meets Rule 144 disclosure obligations; provides transparency on insider compensation-derived sales.

The notice identifies the broker, sale timing, acquisition method (restricted stock vesting) and prior disposals, and includes the standard insider certification about material nonpublic information. This is a routine compliance disclosure that documents an insider monetizing vested equity awarded as compensation. The record of both the proposed sale and the earlier June sale is consistent with required transparency under securities rules.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	4700	35650.91	176690662	09/02/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/29/2025	Restricted Stock Vesting	Issuer			4700	08/29/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kelly Bliss 155 E 44th Street Floor 17 New York NY 10017	Common	06/02/2025	4653	31919.58

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TDOC Form 144 disclose about the proposed sale?

It reports a proposed sale of 4,700 common shares via Fidelity with an aggregate market value of $35,650.91 to be sold approximately on 09/02/2025 on the NYSE.

How were the shares being sold by the TDOC insider acquired?

The shares were acquired on 08/29/2025 through restricted stock vesting and the consideration is listed as compensation.

Did the filer recently sell other Teladoc shares?

Yes. The filing discloses a sale of 4,653 shares on 06/02/2025 for gross proceeds of $31,919.58 by Kelly Bliss.

How many Teladoc shares were reported outstanding in the filing?

The filing lists 176,690,662 shares outstanding.

Which broker is handling the proposed sale?

The broker named is Fidelity Brokerage Services LLC with an address at 900 Salem Street, Smithfield, RI; the sale is to occur on the NYSE.